repaglinide has been researched along with vildagliptin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Favarato, D; Garzillo, CL; Girardi, P; Hueb, W; Kalil Filho, R; Lima, EG; Rahmi, RM; Ramires, JA; Rezende, PC; Strunz, CM; Takiuti, M; Uchida, AH | 1 |
| Anwar, A; Khan, NA; Raza Shah, M; Siddiqui, R | 1 |
| Anuar, TS; Khan, NA; Maciver, SK; Mungroo, MR; Siddiqui, R; Tong, T | 1 |
4 other study(ies) available for repaglinide and vildagliptin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effect of hypoglycemic agents on ischemic preconditioning in patients with type 2 diabetes and symptomatic coronary artery disease.
Topics: Adamantane; Aged; Carbamates; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Ischemic Preconditioning; Male; Middle Aged; Nitriles; Piperidines; Prospective Studies; Pyrrolidines; Vildagliptin | 2013 |
Antidiabetic Drugs and Their Nanoconjugates Repurposed as Novel Antimicrobial Agents against Acanthamoeba
Topics: Acanthamoeba castellanii; Amebicides; Anti-Infective Agents; Carbamates; HeLa Cells; Humans; Hypoglycemic Agents; Metal Nanoparticles; Nanoconjugates; Piperidines; Silver; Sulfonylurea Compounds; Vildagliptin | 2019 |
Development of anti-acanthamoebic approaches.
Topics: Acanthamoeba castellanii; Acanthamoeba Keratitis; Acarbose; Antiprotozoal Agents; Carbamates; Cell Line; Contact Lens Solutions; Contact Lenses; HaCaT Cells; Humans; Indenes; Inositol; Nanoparticles; Piperidines; Sulfonylurea Compounds; Triazines; Vildagliptin | 2021 |